F. Caravaca et al., Does angiotensin converting enzyme-inhibitor therapy influence the prevalence and severity of anemia in predialysis renal failure patients?, NEFROLOGIA, 19(6), 1999, pp. 538-544
Even though erythropoietin (EPO) deficiency is the main factor implicated i
n the anemia secondary to renal failure, many other factors can influence i
ts severity. Among these factors, ACE-inhibitors have been shown to aggrava
te the anemia or to cause resistance to rHuEPO therapy.
This study was designed to determine if ACE-inhibitors play any independent
and significant role in the severity of the anemia in advanced renal failu
re patients. The study group consisted of 134 patiens with creatinine clear
ance less than 30 ml/min who had never been treated with rHuEPO or dialysis
. Multiple logistic regression analysis was utilized to establish the best
determinants for a hematocrit (Hct) less than 30% or Hct less than 25%. The
variables included in the model were: demographics, Ccr, albumin, bicarbon
ate, ferritin, transferrin saturation, PTH, 24 h. urine protein excretion,
the diagnosis of glomerulopehritis vs other, diabetes vs other, polycystic
kidney disease vs other, vascular renal disease vs other, ACE-inhibitors, s
tandarized dose of ACE-inhibitors, calcium-channel blockers, diuretics, ant
iplatelet or anticoagulant prescriptions.
The mean Hct was 31,0 +/- 5,4%. Fifteen patients had Hct less than 25%, and
in 55 the Hct was less than 30%. Sixty-seven patients were on ACE-inhibito
rs. The main determinants for a Hct less than 25% was the 24 h. urinary pro
tein excretion in mg (odds ratio: 1,0002; p = 0.019). The main variable whi
ch fitted the best equation for a Hct less than 30%; was the diagnosis of r
enal vascular disease (odds ratio: 0. 143; p = 0.0042). The prescription or
dosage of ACE-inhibitors were not related the severity of anemia in the wh
ole group or in each subgroup according to the cause of renal failure.
In conclusion, ACE-inhibitor prescription does not appear to play any signi
ficant role in the severity of the anemia, of end-stage renal failure patie
nts when it is weigthed against other potential influences.